Pfizer Announces Prevnar Data and 2 Dow Movers Trading Today
Pfizer (NYSE:PFE) reported top-line data which assesses immunogenicity, tolerability, and safety of Prevenar 13 in adults from18 to 49 years of age. These data back a recent regulatory submission for the expansion of the indication of Prevenar 13 in the European Union to include adults between 18 and 49 years old and will be used in support of similar planned submissions in other countries globally in the future. The primary objective of this evaluation was to show that the immune response to Prevenar 13 in the cited group is noninferior to the immune response to Prevenar 13 in the 60 to 64 year old age group as measured by serotype specific opsonophagocytic assay titers one month following vaccination. This objective was met for all 13 serotypes in Prevenar 13, which is currently approved in more than 110 countries for use in infants and young children, and in more than 70 countries for use in adults 50 years of age and older. Additionally, Prevenar 13 may be obtained through the World Health Organization pre-qualification program for active immunization of infants and young children along with adults who are 50 years and older.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
AT&T (NYSE:T) will sell Nokia Corporation’s (NYSE:NOK) first device that runs on Windows Phone 8 software for the domestic market, say sources to Bloomberg.
Verizon Communications (NYSE:VZ): Sprint Nextel Corporation (NYSE:S) Chief Executive Dan Hesse says that deals were coming in the wireless industry in which Sprint would be part. However, with Deutsche Telekom’s (DTEGY) coming merger of its American subsidiary, T-Mobile USA, and with MetroPCS Communications (NYSE:PCS), Sprint was outmaneuvered, which poses questions concerning whether it missed an opportunity to increase its scale so as to better compete against AT&T and Verizon Wireless (NASDAQ:VOD), according to the Wall Street Journal.
Don’t Miss: Here’s a New Treatment for Muscular Dystrophy.